Treating patients with CAR-T :
"We hear it takes a village, and I'm going to tell you, it takes a city"

David Porter, M.D. (University of Pennsylvania), in an interview for Fierce Pharma1

With HarmonyCell, deliver the best of cell and gene therapies without being overwhelmed by the complexity of these treatment journeys

Total hourly workload for a department treating 17,5 patients CAR-T per year

3000+ clinical trials for cell and gene therapies over 5 years3

The potential new indications and the constantly increasing patient population: an increasing burden for care services

The only free medical platform that simplifies the coordination of treatment journeys for cell and gene therapies

Imagined and created to be used by both qualified and referral centers

Refer your patients quickly and easily through HarmonyCell thanks to a formalized process

Adopt HarmonyCell to develop your activities in cell and gene therapies and reduce the associated workload

Our priorities: security and regulatory compliance

A secure and reliable platform for trusted care

Secure hosting

Data stored on certified HDS servers, specially designed for medical data storing, meeting regulatory requirements and ensuring maximum security

Secure connection

Access and authentication are restricted to authorized healthcare professionals using industry-standard identity verification systems compliant with local regulations

Regulatory compliance

Platform compliant with applicable regulations for e-health solutions, including secure patient identity verification through authorized national healthcare systems

A simple, fast and progressive implementation in your practice

  1. Step 1 – Information meeting to answer your questions and explain the implementation steps
  2. Step 2 – Registration, staff training and small-scale testing of HarmonyCell in real conditions
  3. Step 3 – When you are ready, complete integration of HarmonyCell into your current practices for cell and gene therapies

Références

  1. Fierce Pharma (2023). Mid-decade crisis looms for CAR-T cell therapy. Lien
  2. Fleta et al (2023). Impacts organisationnels et budgétaires de la mise en place des thérapies CAR-T cells au sein d'un centre hospitalier académique français. Lien
  3. IQVIA Institute (2023). Strengthening Pathways for Cell and Gene Therapies. Lien